ADPT - Adaptive Biotechnologies Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
27.27
-1.08 (-3.81%)
At close: 4:00PM EST

27.27 0.00 (0.00%)
After hours: 4:48PM EST

Stock chart is not supported by your current browser
Previous Close28.35
Open29.74
Bid27.10 x 800
Ask28.00 x 2900
Day's Range26.26 - 30.59
52 Week Range24.05 - 55.12
Volume1,043,665
Avg. Volume521,455
Market Cap3.389B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.51
Earnings DateNov 12, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.75
  • GlobeNewswire

    Adaptive Biotechnologies Corporation Reports Third Quarter 2019 Financial Results

    SEATTLE, Nov. 12, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended September 30,.

  • 4 Biotech Stocks That Could Keep Beating Wall Street
    Zacks

    4 Biotech Stocks That Could Keep Beating Wall Street

    The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

  • GlobeNewswire

    Adaptive Biotechnologies to Report Third Quarter Financial Results on November 12, 2019

    Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the third quarter of 2019 after market close on Tuesday, November 12, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3698520). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • Hedge Funds Have Never Been This Bullish On Adaptive Biotechnologies Corporation (ADPT)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Adaptive Biotechnologies Corporation (ADPT)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
    Zacks

    Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

    Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

  • Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?
    Simply Wall St.

    Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?

    If you want to know who really controls Adaptive Biotechnologies Corporation (NASDAQ:ADPT), then you'll have to look...

  • Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
    Zacks

    Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

    Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.

  • GlobeNewswire

    Adaptive Biotechnologies Enters Partnership with Illumina to Develop Distributable IVD Test Kits for clonoSEQ and immunoSEQ Dx

    Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a partnership with Illumina, Inc. (ILMN) to develop in-vitro diagnostic (IVD) test kits for Adaptive’s current and future portfolio of next-generation sequencing (NGS)-based immunodiagnostics. The test kits under development would expand the availability of Adaptive’s clonoSEQ® Assay for assessing and monitoring minimal residual disease (MRD) for the management of patients with certain blood cancers and immunoSEQ Dx™ Assay for pipeline applications.

  • GlobeNewswire

    Adaptive Biotechnologies Enters Partnership for Use Of clonoSEQ® as Preferred MRD Test for Drug Development Across Amgen’s Hematology Franchise

    Adaptive Biotechnologies Corporation (ADPT) today announced it has entered into a global agreement with Amgen for the use of Adaptive’s next-generation sequencing (NGS)-based clonoSEQ® Assay to assess minimal residual disease (MRD) across multiple drug development programs within the Amgen hematology portfolio.

  • Here's Why Adaptive Biotechnologies Rose 31.9% in August
    Motley Fool

    Here's Why Adaptive Biotechnologies Rose 31.9% in August

    The diagnostic company reported second-quarter 2019 operating results, but shares tumbled in early September.

  • Andreas Halvorsen's Top 5 Buys of the 2nd Quarter
    GuruFocus.com

    Andreas Halvorsen's Top 5 Buys of the 2nd Quarter

    Viking Global’s top buys include 3 IPOs Continue reading...

  • GlobeNewswire

    Adaptive Biotechnologies Corporation Reports Second Quarter 2019 Financial Results

    SEATTLE, Aug. 13, 2019 -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today reported financial results for the quarter ended June 30, 2019..

  • GuruFocus.com

    Ron Baron Comments on Adaptive Biotechnologies Corp

    Guru stock highlight Continue reading...

  • New Listings Stink Up Earnings Season After Reports Disappoint
    Bloomberg

    New Listings Stink Up Earnings Season After Reports Disappoint

    (Bloomberg) -- Shares in three of the year’s hottest IPOs, Uber Technologies Inc., Revolve Group Inc. and Fastly Inc., plunged Friday as the latest batch of newly listed companies reported some of the most disappointing results this earnings season.Uber shares ended Friday 6.8% lower after the ride-hailing company missed sales estimates. Revolve fell 15.6% after the fashion e-tailer reported earnings below expectations. And Fastly, which saw its shares dip below its IPO price intraday, declined 18.1% after reporting lighter than expected margins.The disappointment spread to other IPOs that have not even reported yet, with RealReal Inc. shares tumbling 23% to below its IPO price of $20.Call it an upset, given the hype that tends to follow IPOs. Among the nearly 20 freshly listed companies that reported earnings this week, the majority fell in the next session. IPOs are rising 0.2% on average following reports, lagging behind S&P 500 stocks, which climbed 5.3% on average, according to data compiled by Bloomberg.Other newcomers on deck to report earnings include Adaptive Biotechnologies Corp., Greenlane Holdings Inc., RealReal Inc., and Grocery Outlet Holding Inc. They are among the more well-received IPOs of this year with stocks that opened at least 40% above their offer prices. All are first-time reporters.Cross-border IPOs will be tested as well when China’s big brands So-Young International Inc. and Luckin Coffee Inc. do their show-and-tell.(Updates shares in 1st and 2nd paragraphs, adds RealReal shares in 3rd.)\--With assistance from Drew Singer.To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Jennifer Bissell-Linsk, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • GlobeNewswire

    Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub

    SEATTLE, Aug. 07, 2019 -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial-stage biotechnology company that reads and translates the genetic code of the.

  • GlobeNewswire

    Adaptive Biotechnologies to Report Second Quarter Financial Results on August 13, 2019

    Adaptive Biotechnologies (ADPT) today announced that it will report financial results for the second quarter of 2019 after market close on Tuesday, August 13, 2019. Investors interested in listening to the conference call may do so by dialing (800) 361-2311 for U.S. callers or (409) 937-8761 for international callers (Conference ID: 3095467). Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.

  • GlobeNewswire

    Adaptive Biotechnologies Receives New York State CLEP Approval for clonoSEQ to Detect and Monitor Minimal Residual Disease (MRD) in Patients with Certain Blood Cancers

    Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system with the goal of developing personalized diagnostics and therapeutics to improve patient lives, today announced that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved the clonoSEQ® Assay for the detection and monitoring of minimal residual disease (MRD) in patients with B-cell blood cancers.

  • 3 Stocks the World's Best Investors Are Buying Right Now
    Motley Fool

    3 Stocks the World's Best Investors Are Buying Right Now

    This natural gas stock, blood diagnostic company, and gold miner have caught the eye of some of the top investors.

  • Next-Generation Xbox Unveiled as China Production Cuts Loom
    Market Realist

    Next-Generation Xbox Unveiled as China Production Cuts Loom

    Microsoft (MSFT) has unveiled its next-generation video game console in the midst of contemplating Xbox production cuts in China.

  • Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today
    Motley Fool

    Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today

    Despite a strong day for the market, these stocks lagged behind.

  • GlobeNewswire

    Adaptive Biotechnologies Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Adaptive Biotechnologies Corporation (ADPT) (“Adaptive”), a commercial-stage biotechnology company that reads and translates the genetic code of the adaptive immune system to develop personalized diagnostics and therapeutics to improve patient lives, today announced the closing of its initial public offering of 15,000,000 shares of common stock, and the exercise in full of the underwriters’ option to purchase 2,250,000 additional shares of its common stock, at a public offering price of $20.00 per share. Goldman Sachs & Co. LLC, J.P. Morgan and BofA Merrill Lynch acted as joint lead book-running managers for the offering.